Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Molecular Taxonomic Features of MDS/CMML Patients Influence Response to Hypomethylating Agent Therapy and Clinical Outcomes

Alfonso Molina, Vishesh Khanna, Rong Lu, Henning Stehr, Brent Tan, Peter L. Greenberg

Blood (2024) 144 (Supplement 1): 4588.

https://doi.org/10.1182/blood-2024-202547

Published: 2024

Journal Articles

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Elsa Bernard, Robert P. Hasserjian, Peter L. Greenberg, Juan E. Arango Ossa, Maria Creignou, Heinz Tuechler, Jesus Gutierrez-Abril, Dylan Domenico, Juan S. Medina-Martinez, Max Levine, Konstantinos Liosis, Noushin Farnoud, Maria Sirenko, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Yasuhito Nannya, Olivier Kosmider, Matilde Y. Follo, Felicitas Thol, Lurdes Zamora, Ronald F. Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Seishi Ogawa, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2024) 144 (15): 1617–1632.

https://doi.org/10.1182/blood.2023023727

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular and clinical presentation of UBA1 -mutated myelodysplastic syndromes

Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E. Arango Ossa, Olivier Kosmider, Robert Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Birgitta Sander, Elisa Orna, Katharina Zoldan, Lea Naomi Eder, Wolfgang R. Sperr, Renate Thalhammer, Christina Ganster, Lionel Adès, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2024) 144 (11): 1221–1229.

https://doi.org/10.1182/blood.2023023723

Published: 2024

Includes: Supplemental data

Journal Articles

How I reduce and treat posttransplant relapse of MDS

Alain Mina, Peter L. Greenberg, H. Joachim Deeg

Blood (2024) 143 (14): 1344–1354.

https://doi.org/10.1182/blood.2023023005

Published: 2024

Journal Articles

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes

Amy E. DeZern, Peter L. Greenberg

Blood (2023) 142 (26): 2258–2267.

https://doi.org/10.1182/blood.2023020081

Published: 2023

Journal Articles

Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications

Elsa Bernard, Robert Hasserjian, Peter L. Greenberg, Juan E Arango Ossa, Maria Creignou, Yasuhito Nannya, Heinz Tuechler, Juan S Medina-Martínez, Max F Levine, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Olivier Kosmider, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K Elias, Detlef Haase, Maria Sirenko, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Eva Hellstrom Lindberg, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 997.

https://doi.org/10.1182/blood-2023-186863

Published: 2023

Journal Articles

UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes

Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango Ossa, Olivier Kosmider, Robert Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Andrea Pellagatti, Harold K Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B Beck, Eva Hellstrom Lindberg, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2023-182949

Published: 2023

Journal Articles

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Guillermo Garcia-Manero, Melissa Ooi, Zhentang Lao, Harinder Gill, Yasmin Abaza, Maximilian Stahl, Tamanna Haque, Amy E. DeZern, Peter L. Greenberg, Marc Pelletier, Arti Singh, Daniel Carreon, Valerie Beaulieu, Janghee Woo

Blood (2023) 142 (Supplement 1): 3250.

https://doi.org/10.1182/blood-2023-174642

Published: 2023

Journal Articles

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Blood (2022) 140 (20): 2170–2174.

https://doi.org/10.1182/blood.2022016171

Published: 2022

Includes: Supplemental data

Journal Articles

Characterization of Clinical, Molecular, and Prognostic Features of the W.H.O. 2022 Classification System for Myelodysplastic Neoplasms (MDS)

Vishesh Khanna, Rong Lu, Jyoti Kumar, Henning Stehr, Michael A Spinner, Oscar Silva, Sebastian Fernandez-Pol, Jean S Oak, Brent Tan, Peter L Greenberg

Blood (2022) 140 (Supplement 1): 6955–6957.

https://doi.org/10.1182/blood-2022-165841

Published: 2022

Journal Articles

Correlation of Mutational Profiles and Cytogenetics with Morphologic Dysplasia in Myelodysplastic Syndromes

Jyoti Kumar, Vishesh Khanna, Rong Lu, Henning Stehr, Michael A Spinner, Oscar Silva, Sebastian Fernandez-Pol, Jean S Oak, Peter L Greenberg, Brent Tan

Blood (2022) 140 (Supplement 1): 4053–4055.

https://doi.org/10.1182/blood-2022-160237

Published: 2022

Journal Articles

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Blood (2022) 140 (Supplement 1): 6976–6978.

https://doi.org/10.1182/blood-2022-158671

Published: 2022

Journal Articles

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Maria Sirenko, Elsa Bernard, David B. Beck, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango, Olivier Kosmider, Robert P. Hasserjian, Martin Jadersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo G. Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio Pires de Souza Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 9785–9788.

https://doi.org/10.1182/blood-2022-162397

Published: 2022

Journal Articles

Epidemiologic Evaluation of Clinical Outcomes in Ethnic Minorities with Myelodysplastic Syndromes

Alfonso Molina, Lan Xiao, Quinn T. Ostrom, Lisa G. Rosas, Peter L. Greenberg

Blood (2021) 138 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2021-152011

Published: 2021

Journal Articles

MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity

Michael A Spinner, Steven A Schaffert, Henning Stehr, Marianne T Santaguida, Ryosuke Kita, Alexey Aleshin, James L Zehnder, Peter L. Greenberg

Blood (2021) 138 (Supplement 1): 4645.

https://doi.org/10.1182/blood-2021-152103

Published: 2021

Journal Articles

Correlating Clinical and Genomic Features with E x Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms

Michael A Spinner, MD, Steven A Schaffert, PhD, Alexey Aleshin, MD MBA, Marianne T Santaguida, PhD, Hiroomi Tada, MDPhD, Peter L. Greenberg

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140095

Published: 2020

Journal Articles

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-137232

Published: 2020

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

https://doi.org/10.1182/blood.2020004850

Published: 2020

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

NARROW

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Molecular Taxonomic Features of MDS/CMML Patients Influence Response to Hypomethylating Agent Therapy and Clinical Outcomes

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Molecular and clinical presentation of UBA1 -mutated myelodysplastic syndromes

How I reduce and treat posttransplant relapse of MDS

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes

Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications

UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Characterization of Clinical, Molecular, and Prognostic Features of the W.H.O. 2022 Classification System for Myelodysplastic Neoplasms (MDS)

Correlation of Mutational Profiles and Cytogenetics with Morphologic Dysplasia in Myelodysplastic Syndromes

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Epidemiologic Evaluation of Clinical Outcomes in Ethnic Minorities with Myelodysplastic Syndromes

MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity

Correlating Clinical and Genomic Features with E x Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only